Xeris Biopharma Announces Board Changes and Compensation Updates

TL;DR

Xeris Biopharma shakes up the board and adjusts exec pay. Big changes coming?

AI Summary

On June 5, 2024, Xeris Biopharma Holdings, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing includes the election of new directors and updates to compensatory arrangements for certain officers. It also addresses the submission of matters to a vote of security holders.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy, governance, and future performance, impacting investor confidence.

Risk Assessment

Risk Level: medium — Changes in board and executive compensation can indicate strategic shifts or internal challenges that may affect the company's future performance.

Key Players & Entities

• Xeris Biopharma Holdings, Inc. (company) — Registrant
• June 5, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share XERS The Nasdaq Global Select

Filing Documents

• xers-20240605.htm (8-K) — 48KB
• ex101xeris-amendmentno1t.htm (EX-10.1) — 3KB
• ex101xeris-amendmentno1t001.jpg (GRAPHIC) — 198KB
• 0001867096-24-000102.txt ( ) — 482KB
• xers-20240605.xsd (EX-101.SCH) — 2KB
• xers-20240605_def.xml (EX-101.DEF) — 15KB
• xers-20240605_lab.xml (EX-101.LAB) — 26KB
• xers-20240605_pre.xml (EX-101.PRE) — 16KB
• xers-20240605_htm.xml (XML) — 3KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. The Company held its Annual Meeting on June 5, 2024. As of April 12, 2024, the record date for the Annual Meeting, there were 148,253,615 shares of the Company's common stock outstanding and entitled to vote at the Annual Meeting. The Company's stockholders voted on the following matters, which are described in detail in the Company's Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 23, 2024: (i) to elect Paul R. Edick, Ricki Fairley and Marla S. Persky as Class III directors of the Company to serve until the 2027 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal ("Proposal 1"); (ii) to ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 ("Proposal 2"); to indicate, (iii) on a non-binding advisory basis, the preferred frequency of future stockholder advisory votes on the compensation of our named executive officers ("Proposal 3"); (iv) to approve, on a non-binding advisory basis, the compensation of our named executive officers ("Proposal 4") and (v) to approve an amendment to the Xeris Pharmaceuticals, Inc. 2018 employee stock purchase plan (1) to remove the "evergreen" provision which provides for annual increases in the aggregate number of shares available for issuance thereunder and (2) increase the aggregate number of shares available thereunder by 6,636,632 additional shares ("Proposal 5"). The Company's stockholders approved the Class III director nominees recommended for election in Proposal 1 at the Annual Meeting. The Company's stockholders voted for the Class III directors as follows*: Class III Director Nominee For Withhold Broker Non-Votes Paul R. Edick 58,524,066 6,505,672 36,161,541 Ricki Fairley 58,511,772 6,520,445 36,159,062 Marla S. P

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 First Amendment to Xeris Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 5, 2024 Xeris Biopharma Holdings, Inc. By: /s/ Steven M. Pieper Name: Steven M. Pieper Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR